Medicare Enrolled
Dr. Robyn Young, M.D.
Hematology & Oncology · Fort Worth, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Young from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Young?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Young
Dr. Robyn Young is a hematology & oncology specialist in Fort Worth, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Young performed 8,937 Medicare services across 1,151 unique beneficiaries.
Between the years covered by Open Payments, Dr. Young received a total of $107,539 from 66 pharmaceutical and/or device companies across 446 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Young is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 37% volume in TX
$107,539 industry payments
Medicare Practice Summary
Medicare Utilization ↗8,937
Medicare services
Top 37% in TX for hematology & oncology
1,151
Unique beneficiaries
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~470 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 4,020 | $19 | $40 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
980 | $0 | $5 |
| Anti-nausea injection (Aloxi/palonosetron) | 830 | $1 | $52 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
536 | $87 | $275 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
424 | $6 | $300 |
| COVID-19 test, self-administered An FDA-approved, authorized, or cleared test kit for nonprescription self-administered and self-collected use. This code represents the provision of one test count. |
340 | $12 | $30 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
316 | $131 | $350 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
223 | $12 | $70 |
| Principal care management for high-risk disease, first 30 minutes This service covers the initial 30 minutes of clinical staff time per calendar month to manage a single high-risk disease. It is directed by a healthcare professional. |
166 | $47 | $160 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
148 | $10 | $60 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
125 | $99 | $409 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
118 | $45 | $190 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
82 | $1 | $10 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
78 | $22 | $100 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
70 | $1 | $5 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
56 | $52 | $401 |
| Additional 30 minutes of principal care management This service covers each additional 30 minutes of clinical staff time directed by a healthcare professional for managing a single high-risk disease, billed per calendar month. |
56 | $36 | $120 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
46 | $25 | $90 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
45 | $58 | $175 |
| Whole body bone and joint nuclear medicine scan A nuclear medicine imaging test that uses a radioactive tracer to create pictures of the entire skeleton and joints. This scan helps evaluate bone health and detect abnormalities throughout the body. |
40 | $182 | $800 |
| Technetium Tc-99m medronate diagnostic injection An injection of Technetium Tc-99m medronate used for diagnostic imaging studies. The dose administered is up to 30 millicuries per study. |
39 | $48 | $125 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
36 | $137 | $681 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
30 | $62 | $175 |
| New patient office visit, complex (60-74 min) | 24 | $170 | $500 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
23 | $22 | $93 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 22 | $106 | $450 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
21 | $1,160 | $4,069 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
16 | $48 | $161 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
14 | $61 | $250 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
13 | $52 | $150 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.6% high complexity
78.2% medium
18.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$107,539
Total received (2018-2024)
Avg $15,363/year across 7 years
Top 6% in TX for hematology & oncology
66
Companies
446
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$90,791 (84.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,376 (10.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,453 (3.2%)
Other
Charitable contributions, space rental, and other categories
$1,919 (1.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$9,023
2023
$10,248
2022
$11,202
2021
$6,424
2020
$504
2019
$32,448
2018
$37,688
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$66,081
Novartis Pharmaceuticals Corporation
$18,088
Stemline Therapeutics Inc.
$6,106
AstraZeneca Pharmaceuticals LP
$3,550
PFIZER INC.
$3,436
PUMA BIOTECHNOLOGY, INC.
$1,869
Daiichi Sankyo Inc.
$892
Puma Biotechnology, Inc.
$715
Lilly USA, LLC
$494
Roche Products Limited
$458
Genentech, Inc.
$404
Celgene Corporation
$370
GENZYME CORPORATION
$278
E.R. Squibb & Sons, L.L.C.
$250
NOVARTIS PHARMACEUTICALS CORPORATION
$250
Gilead Sciences, Inc.
$247
GlaxoSmithKline, LLC.
$242
Takeda Pharmaceuticals U.S.A., Inc.
$218
Tactile Systems Technology Inc
$203
Janssen Biotech, Inc.
$191
Merck Sharp & Dohme LLC
$190
Alexion Pharmaceuticals, Inc.
$184
Tempus AI, Inc
$168
Clovis Oncology, Inc.
$145
SERVIER PHARMACEUTICALS LLC
$144
ABBVIE INC.
$139
AstraZeneca UK Limited
$135
Seattle Genetics, Inc.
$124
EMD Serono, Inc.
$117
Adaptive Biotechnologies Corporation
$116
Verastem, Inc.
$115
TESARO, Inc.
$114
AbbVie, Inc.
$110
Deciphera Pharmaceuticals Inc.
$106
Eisai Inc.
$96
SOBI, INC
$84
Karyopharm Therapeutics Inc.
$84
Seagen Inc.
$82
Incyte Corporation
$78
Amgen Inc.
$65
PharmaEssentia USA Corporation
$64
Kite Pharma, Inc.
$56
TerSera Therapeutics LLC
$52
Boehringer Ingelheim Pharmaceuticals, Inc.
$48
Foundation Medicine, Inc.
$44
TAIHO ONCOLOGY, INC.
$41
Epizyme, Inc.,
$38
Genmab U.S., Inc.
$36
Kyowa Kirin, Inc.
$33
Bayer HealthCare Pharmaceuticals Inc.
$31
Sun Pharmaceutical Industries Inc.
$31
Blueprint Medicines Corporation
$29
AbbVie Inc.
$29
BeiGene USA, Inc.
$26
Bayer Healthcare Pharmaceuticals Inc.
$25
Regeneron Healthcare Solutions, Inc.
$23
ARRAY BIOPHARMA INC
$23
JAZZ PHARMACEUTICALS INC.
$23
Spectrum Pharmaceuticals Inc.
$22
SANOFI-AVENTIS U.S. LLC
$22
Rigel Pharmaceuticals, Inc.
$19
Exelixis Inc.
$19
Merck Sharp & Dohme Corporation
$19
ADC Therapeutics America, Inc.
$16
AIMMUNE THERAPEUTICS, INC.
$16
Pharmacyclics LLC, an AbbVie Company
$13
Top 3 companies account for 83.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALPROLIX · AYVAKIT · Abraxane · BESREMI · BLENREP · BRUKINSA · CALQUENCE · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELREXFIO · ENHERTU · Enhertu · Epkinly · FARESTON · FOUNDATIONONE · Flexitouch Plus · GAVRETO · GILOTRIF · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · Itovebi · JAKAFI · JAYPIRCA · JEVTANA · KEYTRUDA · KISQALI · Kadcyla · Kovaltry · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NATRELLE SALINE-FILLED BREAST IMPLANTS · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · Orserdu · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · Rebif · Revlimid · Rubraca · SANCUSO · SARCLISA · TAGRISSO · TASIGNA · TAXOTERE · TAZVERIK · TUKYSA · Tavalisse · Tibsovo · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VONVENDI · Vanflyta · Venclexta · XALKORI · XPOVIO · Xofigo · YONSA · Yescarta · ZEJULA · ZENPEP · ZEPZELCA · ZOLADEX · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (84%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 6% for hematology & oncology in TX.
Equivalent to $1,203 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
47
Per 100K population
2.2
County median income
$81,905
Nearest hospital
JPS HEALTH NETWORK
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Young is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 6% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Young experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Young performed 4,020 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Young receive payments from pharmaceutical companies?
Yes. Dr. Young received a total of $107,539 from 66 companies across 446 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Young's costs compare to other hematology & oncology specialists in Fort Worth?
Dr. Young's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Young) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Fort Worth
Browse hematology & oncology specialists in Fort Worth ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Stemline Therapeutics Inc. Payments to Doctors
See all physicians who received payments from Stemline Therapeutics Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology